Abstract
The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Keywords: blood-brain barrier, drug efflux, drug delivery, fatty acylation, nanoge, nanoparticles, pluronic block copolymers, poloxamer.
Current Pharmaceutical Design
Title: New Technologies for Drug Delivery Across the Blood Brain Barrier
Volume: 10 Issue: 12
Author(s): A. V. Kabanov and E. V. Batrakova
Affiliation:
Keywords: blood-brain barrier, drug efflux, drug delivery, fatty acylation, nanoge, nanoparticles, pluronic block copolymers, poloxamer.
Abstract: The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Export Options
About this article
Cite this article as:
Kabanov V. A. and Batrakova V. E., New Technologies for Drug Delivery Across the Blood Brain Barrier, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384826
DOI https://dx.doi.org/10.2174/1381612043384826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural Changes in Alzheimers Disease Brain Microvessels
Current Alzheimer Research Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease
Current Alzheimer Research Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Subject Index to Volume 9
Current Pharmaceutical Design Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia
Current Pharmaceutical Design Translational Therapeutic Str ategies in Amyotrophic Lateral Sclerosis
Mini-Reviews in Medicinal Chemistry Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy
Current Drug Targets The Blood-Brain Barrier in NeuroAIDS
Current HIV Research Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Stem Cells with Neurogenic Potential and Steroid Hormones
Current Topics in Medicinal Chemistry Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets